A Promising Treatment Option for Patients Diagnosed with Head-and-neck Cancer

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/35/b5/6c/35b56c12-b5c4-1262-ae78-4c95e2d5a243/mza_354984677533109284.jpg/600x600bb.jpg

The Onco'Zine Brief

Peter Hofland

107 episodes

1 month ago

The Onco'Zine Brief is an interview and discussion program presented by Peter Hofland and covers a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world.

The Onco'Zine Brief is a sponsor-supported, program for healthcare professionals involved in the management and care of cancer patients as well as cancer patients and their family and friends. If you like to join us as a sponsor or advertisers, download our media kit (https://adc.expert/oncozine_media_kit).

If you are living in the US, sign up for our newsletter by texting the words CANCER to 66866.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.

Science

Health & Fitness

RSS

All content for The Onco'Zine Brief is the property of Peter Hofland and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Health & Fitness

https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/014ad22c914b7bf8c098f8de9e4a8f1a.jpg

A Promising Treatment Option for Patients Diagnosed with Head-and-neck Cancer

The Onco'Zine Brief

48 minutes

4 years ago

A Promising Treatment Option for Patients Diagnosed with Head-and-neck Cancer

In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Eyal Talor, Ph.D., a clinical immunologist with over 25 years of hands-on management experience in clinical research and drug development. Talor joined CEL-SCI in October 1993 and was promoted to Chief Scientific Officer in October 2009. CEL-SCI is developing a new immunotherapeutic drug for the treatment of cancer, autoimmune diseases, and infectious diseases. In today’s program, Hofland and Talor are talking about one of these agents, an investigational drug called leukocyte interleukin, or Multikine®

Multikine® is currently in late-stage development and is being investigated as a possible new adjuvant therapy for patients diagnosed with head-and-neck cancer and cervical dysplasia.

The published results of clinical studies, including a recently concluded Phase 3 study, are very promising in patients diagnosed with head-and-neck cancer. Patients treated with this new anticancer agent in combination with standard of care (SOC) versus standard of care alone had an overall survival benefit of 14.1% at five years. These results exceeded the predefined 10% overall survival benefit set out for the study population as a whole.

About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: http://www.oncozine.com to download our Media Kit or visit Patreon at https://www.patreon.com/theoncozinebrief to support the program.

For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.